Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1287-1297

  Shapiro, Amy ^a  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

Fc fusion; Hemophilia; Long acting clotting factor; Prolonged half life; RFIXFc; RFVIIIFc

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AREA UNDER THE CURVE; BLEEDING; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

EID: 84881519452     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.819339     Document Type: Review

References (62)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9 (Pubitemid 32497033)
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32
3. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136: 777-87
4. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia a (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10
5. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44 (Pubitemid 47236278)
6. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50 (Pubitemid 34257918)
7. Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the academic achievement in children with hemophilia study. Pediatrics 2001; 108: E105
8. National Hemophilia Foundation, Medical and Scientific Advisory Council. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available from: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid= 1007 [Last accessed 10 January 2013]
9. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2012. Available from: http://www1.wfh.org/publications/files/pdf- 1472.pdf [Last accessed 14 January 2013]
10. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl 4): 131-5
11. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10
12. Lindvall K, Astermark J, Bjorkman S, et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855-9
13. Fisher K. Optmimizing efficacy of factor VIII prophylaxis for severe haemophilia A. Haemophilia 2011; 17(Suppl 3): 9-15
14. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-9 (Pubitemid 36638432)
15. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6
16. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-8 (Pubitemid 40592892)
17. Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745
18. Lenting PJ, VAN Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60 (Pubitemid 46965358)
19. White GC II, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5 (Pubitemid 27289251)
20. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6 (Pubitemid 32677658)
21. Richards M, Altisent C, Batorova A, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473-9 (Pubitemid 47337985)
22. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46 (Pubitemid 38312640)
23. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010; 17: 393-7
24. Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia 2009; 15: 1219-27
25. Lillicrap D. The improved factor concentrate. Hämostaseologie 2009; 29: 71-3
26. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24: 1241-52 (Pubitemid 44564769)
27. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9
28. Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain OglycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108-16
29. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701
30. Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32(Suppl 1): S29-38
31. Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013; 19: 11-20
32. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701
33. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-6
34. Bensen-Kennedy D. Bringing new therapy options to the hemophilia community. Thromb Res 2013; 131(Suppl 2): S15-18
35. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009; 24: 318-32
36. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197: 315-22 (Pubitemid 36184238)
37. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-25 (Pubitemid 47327396)
38. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 2009; 124(Suppl 2): S6-8
39. Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer lasting and more effective therapeutics. Submitted 2013
40. Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005; 15: 5-9 (Pubitemid 40094675)
41. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18: 739-66 (Pubitemid 30365396)
42. McGarry T, Hough R, Rogers S, Rechsteiner M. Intracellular distribution and degradation of immunoglobulin G and immunoglobulin G fragments injected into HeLa cells. J Cell Biol 1983; 96: 338-46 (Pubitemid 13115836)
43. Israel EJ, Taylor S, Wu Z, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997; 92: 69-74 (Pubitemid 27380883)
44. Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric Factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132-42
45. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-64
46. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119: 3024-30
47. Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 2009; 20: 700-7
48. Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov Today 2010; 15: 773-80
49. Swiech K, Picanco-Castro V, Covas DT. Human cells: new platform for recombinant therapeutic protein production. Protein Expr Purif 2012; 84: 147-53
50. Zhang M, Mezo A. Enzymatic release and detection of galactose-alpha- 1,3-galactose (a-Gal) in recombinant FVIII products. Haemophilia 2012; 18(Suppl S3): PO-MO-135
51. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. occurence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 2012; 28: 147-76
52. Brinkhous KM, Sigman JL, Read MS, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2603-10 (Pubitemid 26327511)
53. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6
54. Poon M-C. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006; 12(Suppl 4): 61-9 (Pubitemid 44404841)
55. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7
56. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72
57. BeneFIX. Prescribing Information. 2011. Available from: http://labelingpfizercom/showlabelingaspx?id=492 [Accessed 20 March 2013]
58. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9 (Pubitemid 32243794)
59. Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75
60. Suiter T, Laffan M, Mannucci PM, et al. Recombinant human von Willebrand factor (rVWF): first-in-human study evaluating pharmacokinetics, demonstrating safety and tolerability in type 3 von Willebrand disease. Blood 2010; 116: abstract 237
61. Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-18
62. Ljung R, Auerswald G, Benson G, et al. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013; [Epud ahead of print]